Payment overview · 2025
General Payments
$82.40
4 reported records · 3 companies
Healthcare provider profile · identity verified
Yolanda Bryant, MD
Allopathic & Osteopathic Physicians|Family Medicine · NORTH AUGUSTA, SC · NPI 1023233129
Verified facts
What the public records show
CMS Open Payments records show Yolanda Bryant, MD received $82.40 in general payments during 2025 across 4 reported records.
Exact Sciences Corporation accounted for 53.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lokelma by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $43.76 | 53.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.41 | 24.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.23 | 22.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $82.40 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
41 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 528 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 524 | 53 |
| Sertraline Hcl | Sertraline Hcl | 357 | 28 |
| Levothyroxine Sodium | Levothyroxine Sodium | 333 | 26 |
| Eliquis | Apixaban | 267 | 27 |
| Gabapentin | Gabapentin | 266 | 33 |
| Furosemide | Furosemide | 245 | 31 |
| Carvedilol | Carvedilol | 219 | 24 |
| Trazodone Hcl | Trazodone Hcl | 215 | 21 |
| Lisinopril | Lisinopril | 213 | 26 |
| Omeprazole | Omeprazole | 202 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 200 | 21 |
| Potassium Chloride | Potassium Chloride | 198 | 20 |
| Losartan Potassium | Losartan Potassium | 192 | 30 |
| Mirtazapine | Mirtazapine | 187 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 184 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 178 | 13 |
| Risperidone | Risperidone | 177 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 174 | 20 |
| Donepezil Hcl | Donepezil Hcl | 169 | 16 |
| Allopurinol | Allopurinol | 146 | 14 |
| Metformin Hcl | Metformin Hcl | 132 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 123 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 118 | 14 |
| Divalproex Sodium | Divalproex Sodium | 105 | suppressed |
| Levetiracetam | Levetiracetam | 104 | suppressed |
| Baclofen | Baclofen | 100 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 83 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 78 | suppressed |
| Valsartan | Valsartan | 74 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 70 | suppressed |
| Memantine Hcl | Memantine Hcl | 68 | suppressed |
| Famotidine | Famotidine | 60 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 59 | suppressed |
| Finasteride | Finasteride | 58 | suppressed |
| Olanzapine | Olanzapine | 58 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 57 | 57 |
| Nifedipine Er | Nifedipine | 55 | suppressed |
| Latanoprost | Latanoprost | 51 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 49 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 46 | suppressed |
| Myrbetriq | Mirabegron | 45 | suppressed |
| Bupropion Xl | Bupropion Hcl | 44 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Lamotrigine | Lamotrigine | 44 | suppressed |
| Ozempic | Semaglutide | 41 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 40 | suppressed |
| Haloperidol | Haloperidol | 38 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Spironolactone | Spironolactone | 36 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Calcitriol | Calcitriol | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Simvastatin | Simvastatin | 33 | suppressed |
| Jardiance | Empagliflozin | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Prednisone | Prednisone | 30 | suppressed |
| Amantadine | Amantadine Hcl | 28 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 27 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 26 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Dutasteride | Dutasteride | 25 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 25 | 13 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 25 | suppressed |
| Lactulose | Lactulose | 25 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 21 | 17 |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Ramelteon | Ramelteon | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 19 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 19 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 18 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 13 |
| Atenolol | Atenolol | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Paliperidone Er | Paliperidone | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Clonidine | Clonidine | 13 | suppressed |
| Dulera | Mometasone/Formoterol | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 13 | suppressed |
| Trimethoprim | Trimethoprim | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Carteolol Hcl | Carteolol Hcl | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $82.40 · 4 records | Exact Sciences Corporation | The Cologuard Plus Collection Kit | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error